Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotinamide mononucleotide (Metro International Biotech)
- Development stage
- Phase 2
- Lead developer
- Metro International Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MIB-626 is a proprietary, pharmaceutical-grade oral formulation of **beta-nicotinamide mononucleotide (NMN)**, a direct precursor to **nicotinamide adenine dinucleotide (NAD+)**. Developed by **Metro International Biotech**, MIB-626 is designed to elevate intracellular NAD+ levels, which naturally decline with age and are depleted during metabolic stress. By increasing NAD+ availability, the drug aims to activate **sirtuins** (specifically SIRT1), which are enzymes involved in DNA repair, mitochondrial biogenesis, and cellular metabolism. MIB-626 is currently being evaluated in multiple Phase 2 clinical trials for conditions including **Alzheimer's disease**, **Friedreich's ataxia**, and **acute kidney injury** associated with COVID-19, as well as for improving physical performance and muscle bioenergetics in both healthy young and older adults.
- Other names
- beta-nicotinamide mononucleotideNMNβ-nicotinamide mononucleotide
02
Targets
NAD (Nicotinamide adenine dinucleotide)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on nicotinamide mononucleotide (Metro International Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotinamide mononucleotide (Metro International Biotech).